Suppression of PRL-3 could provide potential opportunity for further improving anti-CML therapy, especially in tumors with Imatinib or TKI resistant BCR-ABL mutants. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.